As reported in 2025, the industry in France held a valuation of USD 18.80 billion.
The France Infusion Services Market will reach USD 38.25 billion by 2033, registering a CAGR of 9.3% during the forecast period.
National reimbursement stability under Assurance Maladie sustains biologic infusion access, particularly for oncology and chronic inflammatory diseases.
Institut National du Cancer publications confirm continued systemic therapy activity across public hospitals, underpinning consistent infusion throughput.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]